After 4S, CARE and LIPID - Is evidence-based medicine being practised?

Atherosclerosis

Volumn 147, Issue SUPPL. 1, 1999, Pages

  Velasco, José A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Cholesterol management; EUROASPIRE survey; PREVENIR survey; PREVESE survey; Secondary CHD prevention

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; EUROPE; EVIDENCE BASED MEDICINE; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MEDICAL PRACTICE; MEDICAL SPECIALIST; MORTALITY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SCIENCE; SECONDARY PREVENTION; SURVIVAL; UNITED STATES;

EID: 0032871750     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00254-3     Document Type: Conference Paper

References (25)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A. et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335:1996;1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339:1998;1349-1357.
4. A European Society of Cardiology survey on secondary prevention of coronary heart disease: principal results. Eur. Heart J. 18:1997;1569-1582.
5. de Velasco J.A., Cosin J., Sendon J.L., de Teresa E. Secondary prevention of myocardial infarction in Spain: the PREVESE study. Rev. Esp. Cardiol. 50:1997;406-415.
6. Cambou JP, Grenier O, Ferrieres J, Danchin N. Secondary prevention of patients with acute coronary syndrome in France: the PREVENIR Survey. The Lancet Conference 1999, Copenhagen, Abstracts book, p. 75.
7. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: prinicpal results. Heart. 75:1996;334-342.
8. Pyorala K., de Backer G., Graham I. On behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and the European Society of Hypertension. Eur. Heart J. 15:1994;1300-1331.
9. Boaz A., Kaduskar S., Rayner M. Coronary heart disease statistics. British Heart Foundation Statistics Database. 1996;British Heart Foundation, London.
10. Prevention of coronary heart disease in clinical practice. Eur. Heart J. 19:1998;1434-1503.
11. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1333-1445.
12. Matching the Intensity of Risk Factor Management with the Hazard for Coronary Disease Events. J. Am. Coll. Cardiol. 27:1996;957-1047.
13. Graille V, Ferrieres J, Marques-Visdal P, Ruldavet JB, Rodier P, Cambou JP. Evolution à long-terme de la prescription medicamenteuse chez 174 patients attients d'infarctus du myocarde suivis pendant 4.5 ans (Etude DEVENIR). (Long term outcome of drug prescription in 174 patientswith myocardial infarction followed-up for 4.5 years (DEVENIR Study), Arch Mal Coeur 1996;89:35-39.
14. Schuster S., Koch A., Burczyk U. Early treatment of acute myocardial infarct: Implementation of therapy guidelines in routine clinical practice, MITRA pilot phase. Z. Kardiol. 86(4):1997;273-283.
15. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 (Suppl.) S1-S9.
16. Mbewu A.F., Durrington P.N., Bulleid S., Mackness M.I. The immediate effect of streptokinase on serum lipoprotein (a) concentration and the effect of myocardial infarction on serum lipoprotein (a), apoplipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis. 103(1):1993;65-71.
17. Burt A., Thornley P., Illingworth D. Stopping smoking after myocardial infarction. Lancet. 1:1974;304-306.
18. Velasco JA, Lopez-Sendon JL, Cosin J, De Teresa E, De Oya M, on behalf of PREVESE Study Group. Epidemiological survey of secondary prevention in acute myocardial infarction patients in Spain. The Lancet Conference 1999, Copenhagen, Abstracts book, p. 75.
19. Vogel R.A. Risk factor intervention and coronary artery disease: clinical strategies. Coronary Artery Dis. 6:1995;46-71.
20. Pearson T.A., Peters T.D. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am. J. Cardiol. 80(8B):1997;45H-52H.
21. Pearson T.A., Kris-Etherton P.M., Shannon B.M. Attainment of low-density lipoprotein (LDL) cholesterol goals in primary care practice: success depends on baseline level of risk (abstract). Circulation. 94:1996;177.
22. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J. Am. Med. Assoc. 269:1993;3015-3033.
23. Marcelino J.J., Feingold K.R. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am. J. Med. 100:1996;605-609.
24. Harnick D.J., Cohen J.L., Schechter C.B. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am. J. Cardiol. 81:1998;1416-1420.
25. Houston-Miller N., Thomas R.J., Superko H.R. Lipid-lowering therapy in post-MI patients: efficacy of a nurse-managed intervention (abstract). Circulation. 84(Suppl. 2):1991;328.